Increased CD4/CD8 Lymphocyte ratio predicts favourable neoadjuvant treatment response in gastric cancer: A prospective pilot study

Table 1 Baseline demographics

Characteristic	N = 431	n/N (missing %)
Age (yr)	65 (60, 75)	43 / 43 (0%)
Sex		43 / 43 (0%)
Female	13 (30%)
Male	30 (70%)
Stage		43 / 43 (0%)
I	11 (26%)
II	10 (23%)
III	8 (19%)
IV	14 (33%)
Grade		43 / 43 (0%)
G1	1 (2.3%)
G2	10 (23%)
G3	31 (72%)
Gx	1 (2.3%)
Tumour location		43 / 43 (0%)
Distal	14 (33%)
Proximal	26 (60%)
Whole stomach	3 (7.0%)
Lauren classification		41 / 43 (4.7%)
Diffuse	26 (63%)
Intestinal	13 (32%)
Mixed	2 (4.9%)
Signet ring cell (present)	26 (63%)	41 / 43 (4.7%)
H. pylori history		32 / 43 (26%)
Negative	22 (69%)
Positive	9 (28%)
Treated	1 (3.1%)
Smoker		40 / 43 (7.0%)
Yes	9 (22%)
No	14 (35%)
Ex	17 (42%)
Smoker (pack years)	7 (0, 32)	39 / 43 (9.3%)
Surgery		43 / 43 (0%)
Total gastrectomy	20 (47%)
Distal gastrectomy	14 (33%)
No resection	9 (21%)
Neoadjuvant chemotherapy	18 (42%)	43 / 43 (0%)
CD4/CD8 ratio (% positive)	1.7 (1.2, 2.8)	42 / 43 (2.3%)
CD4 (% positive)	14 (7, 24)	43 / 43 (0%)
CD8 (% positive)	8 (5, 11)	42 / 43 (2.3%)
Galectin-3 (% positive)	46 (30, 57)	43 / 43 (0%)
E-cadherin (% positive)	18 (6, 28)	43 / 43 (0%)
E-cadherin H-score	22 (7, 40)	43 / 43 (0%)

¹Median (IQR); n (%).